All In Biotech

Drug Trial Radar · NCT06181435

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 589 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

589

Actual

Start

Dec 21, 2023

Primary completion

Nov 25, 2025

Study completion Mar 12, 2026

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Dec 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm monotherapy study for treatment of participants diagnosed with moderate to severe atopic dermatitis (AD), whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for SC injection compared with placebo in participants with moderate to severe AD aged 12 years and older. Study details include: At the end of the treatment period, participants will have an option to enter a separate study: the blinded extension study EFC17600 (ESTUARY). For participants not entering the blinded extension Study EFC17600 (ESTUARY), the study duration will be up to 44 weeks including a 2 to 4-week screening, a 24-week randomized double-blind period, and a 16-week safety follow-up. For participants entering the blinded extension Study EFC17600 (ESTUARY), the study duration will be up to 28 weeks including a 2 to 4-week screening and a 24-week randomized double-blind period. The total treatment duration will be up to 24 weeks. The total number of visits will be up to 10 visits (or 9 visits for those entering the blinded extension study EFC17600 (ESTUARY).

Conditions

  • Dermatitis Atopic

Interventions

  • AmlitelimabDrug

    Pharmaceutical form: Injection solution Route of administration: SC injection

  • PlaceboDrug

    Pharmaceutical form: Injection solution Route of administration: SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. EU, EU reference countries, and Japan: Proportion of participants with Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points at Week 24Time frame: Week 24
  2. EU, EU reference countries, and Japan: Proportion of participants reaching 75% reduction from baseline in Eczema Area and Severity Index (EASI) score (EASI-75) at Week 24Time frame: Week 24
  3. US and US reference countries: Proportion of participants with vIGA-AD of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points at Week 24Time frame: Week 24

Locations

142 sites in 16 countries. Site status is shown where the registry gives one.

  • Center for Dermatology and Plastic Surgery- Site Number : 8401119

    Scottsdale, Arizona

  • Eclipse Clinical Research- Site Number : 8401158

    Tucson, Arizona

  • Torrance Clinical Research- Site Number : 8401027

    Lomita, California

  • Dermatology Research Associates - Los Angeles- Site Number : 8401092

    Los Angeles, California

  • Allergy & Asthma Associates of Southern California - Mission Viejo- Site Number : 8401079

    Mission Viejo, California

  • Cura Clinical Research - Oxnard- Site Number : 8401142

    Oxnard, California

  • Clinical Science Institute- Site Number : 8401028

    Santa Monica, California

  • University of Connecticut Health Center- Site Number : 8401115

    Farmington, Connecticut

  • Pediatric Skin Research- Site Number : 8401198

    Coral Gables, Florida

  • Skin Care Research - Hollywood- Site Number : 8401071

    Hollywood, Florida

  • Savin Medical Group - Miami- Site Number : 8401085

    Miami, Florida

  • Anchor Medical Research- Site Number : 8401300

    Miami, Florida

  • Accel Research - Nona Pediatric Center- Site Number : 8401081

    Orlando, Florida

  • Nuline Clinical Trial Center- Site Number : 8401161

    Pompano Beach, Florida

  • Clinical Research Trials of Florida- Site Number : 8401023

    Tampa, Florida

  • AllerVie Clinical Research - Columbus- Site Number : 8401104

    Columbus, Georgia

  • First Georgia Physician Group- Site Number : 8401190

    Fayetteville, Georgia

  • Access Dermatology- Site Number : 8401296

    Bowling Green, Kentucky

  • MedPharmics - Covington- Site Number : 8401137

    Covington, Louisiana

  • Care Access Research - Marriottsville- Site Number : 8401126

    Marriottsville, Maryland

  • Tufts Medical Center Site Number : 8401201

    Boston, Massachusetts

  • University Of Mississippi Medical Center- Site Number : 8401184

    Jackson, Mississippi

  • Care Access - Hoboken- Site Number : 8401132

    Hoboken, New Jersey

  • University of New Mexico Comprehensive Cancer Center- Site Number : 8401263

    Albuquerque, New Mexico

  • OmeraNY- Site Number : 8401156

    Brooklyn, New York

  • Equity Medical- Site Number : 8401239

    New York, New York

  • Montefiore Medical Center - Moses Campus- Site Number : 8401150

    The Bronx, New York

  • Red River Research Partners- Site Number : 8401196

    Fargo, North Dakota

  • Bexley Dermatology Research- Site Number : 8401051

    Bexley, Ohio

  • Velocity Clinical Research - Springdale- Site Number : 8401153

    Cincinnati, Ohio

  • Dermatology Associates of Plymouth Meeting- Site Number : 8401147

    Plymouth Meeting, Pennsylvania

  • PEAK Research- Site Number : 8401083

    Upper Saint Clair, Pennsylvania

  • Columbia Dermatology & Aesthetics- Site Number : 8401166

    Columbia, South Carolina

  • Health Concepts- Site Number : 8401059

    Rapid City, South Dakota

  • Arlington Research Center- Site Number : 8401248

    Arlington, Texas

  • Derm Texas- Site Number : 8401217

    Dallas, Texas

  • Center for Clinical Studies - Houston - Binz Street- Site Number : 8401063

    Houston, Texas

  • Prolato Clinical Research Center- Site Number : 8401209

    Houston, Texas

  • Sienna Dermatology- Site Number : 8401148

    Missouri City, Texas

  • Progressive Clinical Research - San Antonio- Site Number : 8401016

    San Antonio, Texas

Showing 40 of 142 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.